Literature DB >> 3111279

Treatment of severe obsessive-compulsive disorder with fluvoxamine.

L H Price, W K Goodman, D S Charney, S A Rasmussen, G R Heninger.   

Abstract

Ten obsessive-compulsive patients received single-blind treatment with fluvoxamine, a selective serotonin reuptake inhibitor, for several weeks following at least 2 weeks of placebo. The group showed significant improvement, as measured by several clinical scales and self-ratings; six patients were judged responders. Fluvoxamine appears effective in treating severe obsessive-compulsive disorder.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3111279     DOI： 10.1176/ajp.144.8.1059

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


  12 in total

1.  Electrocardiographic alterations as a result of acute intoxication with fluvoxamine and pipamperone.

Authors:  M Gallerani; L Grassi; F Ferrari; G Calò; R Manfredini
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

2.  Initial orthostatic hypotension as a cause of recurrent syncope: a case report.

Authors:  W Wieling; M P Harms; R A Kortz; M Linzer
Journal:  Clin Auton Res       Date:  2001-08       Impact factor: 4.435

3.  Clinical treatment of obsessive compulsive disorder.

Authors:  Christopher Pittenger; Ben Kelmendi; Michael Bloch; John H Krystal; Vladimir Coric
Journal:  Psychiatry (Edgmont)       Date:  2005-11

Review 4.  A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.

Authors:  L L Carpenter; C J McDougle; C N Epperson; L H Price
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

Review 5.  Treatment of obsessive-compulsive disorder in children and adolescents. A review of the literature.

Authors:  P H Thomsen
Journal:  Eur Child Adolesc Psychiatry       Date:  1996-06       Impact factor: 4.785

Review 6.  Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs.

Authors:  M V Rudorfer; W Z Potter
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

7.  Sleep EEG of patients with obsessive-compulsive disorder.

Authors:  F Hohagen; S Lis; S Krieger; G Winkelmann; D Riemann; R Fritsch-Montero; E Rey; J Aldenhoff; M Berger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

8.  Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study.

Authors:  Tomohiro Kobayashi; Etsuko Hayashi; Midori Shimamura; Mine Kinoshita; Niall P Murphy
Journal:  Psychopharmacology (Berl)       Date:  2008-02-15       Impact factor: 4.530

Review 9.  Current concepts in the pharmacological treatment of obsessive-compulsive disorder.

Authors:  J Zohar; R C Zohar-Kadouch; S Kindler
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 10.  Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder.

Authors:  Christopher Pittenger; John H Krystal; Vladimir Coric
Journal:  NeuroRx       Date:  2006-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.